1
|
Cong X, Zhang Z, Li H, Yang YG, Zhang Y, Sun T. Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium. J Nanobiotechnology 2024; 22:620. [PMID: 39396002 PMCID: PMC11470712 DOI: 10.1186/s12951-024-02892-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2024] [Accepted: 10/01/2024] [Indexed: 10/14/2024] Open
Abstract
Endothelial cells (ECs) are pivotal in maintaining vascular health, regulating hemodynamics, and modulating inflammatory responses. Nanocarriers hold transformative potential for precise drug delivery within the vascular system, particularly targeting ECs for therapeutic purposes. However, the complex interactions between vascular ECs and nanocarriers present significant challenges for the development and clinical translation of nanotherapeutics. This review assesses recent advancements and key strategies in employing nanocarriers for drug delivery to vascular ECs. It suggested that through precise physicochemical design and surface modifications, nanocarriers can enhance targeting specificity and improve drug internalization efficiency in ECs. Additionally, we elaborated on the applications of nanocarriers specifically designed for targeting ECs in the treatment of cardiovascular diseases, cancer metastasis, and inflammatory disorders. Despite these advancements, safety concerns, the complexity of in vivo processes, and the challenge of achieving subcellular drug delivery remain significant obstacles to the effective targeting of ECs with nanocarriers. A comprehensive understanding of endothelial cell biology and its interaction with nanocarriers is crucial for realizing the full potential of targeted drug delivery systems.
Collapse
Affiliation(s)
- Xiuxiu Cong
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, 130061, Jilin, China
- National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, 130062, Jilin, China
| | - Zebin Zhang
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, 130061, Jilin, China
- National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, 130062, Jilin, China
| | - He Li
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, 130061, Jilin, China
| | - Yong-Guang Yang
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, 130061, Jilin, China
- National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, 130062, Jilin, China
- International Center of Future Science, Jilin University, Changchun, 130015, Jilin, China
- State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, 100143, China
| | - Yuning Zhang
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, 130061, Jilin, China.
- National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, 130062, Jilin, China.
| | - Tianmeng Sun
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital, Jilin University, Changchun, 130061, Jilin, China.
- National-Local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, 130062, Jilin, China.
- International Center of Future Science, Jilin University, Changchun, 130015, Jilin, China.
- State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, 130012, Jilin, China.
- State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing, 100143, China.
| |
Collapse
|
2
|
Duo X, Xu Q, Li C, Meng X, Feng Y. CAG peptide functionalized graphene quantum dots-cationic polymer composite gene carriers. J Mater Chem B 2024. [PMID: 38989702 DOI: 10.1039/d4tb00322e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/12/2024]
Abstract
In this study, a targeted graphene quantum dot-cationic polymer composite gene vector with endothelial cell-targeting CAG peptide was successfully designed and prepared. This vector could efficiently bind and deliver the therapeutic gene pZNF580 to endothelial cells (HUVECs). At a concentration of less than 40 μg mL-1, the results of the CCK-8 assay showed that the relative cell viability of each composite gene vector was greater than 80%, and the results of the flow cytometry assay showed that C-GQDs-PEI-PEG-CAG/pZNF580 (88.96%) and N-GQDs-PEI-PLGA-PEG-CAG/pZNF580 (87.70%) treated groups showed significantly higher cell viability than the positive control group Lip2000/pZNF580 (56.76%). The results of in vitro cell transfection and western blot experiments confirmed that the composite gene vector was able to deliver pZNF580 efficiently and enable the high expression of the ZNF580 protein in HUVECs. The results of the EdU assay, wound healing and Transwell experiments indicated that the composite gene vector/pZNF580 nanoparticles (NPs) could significantly promote the proliferation and migration. The results of the EdU method showed that the proliferative ability of C-GQDs-PEI-PLGA/pZNF580 (84.96 ± 1.99%) and N-GQDs-PEI-PLGA/pZNF580 (85.01 ± 1.31%) treatment groups for HUVECs was significantly higher than that of the positive control group Lip2000/pZNF580 (77.89 ± 2.18%). The results of the scratch assay showed that the cell migration rate of C-GQDs-PEI-PLGA-PEG-CAG/pZNF580 (93.08 ± 1.97%) and N-GQDs-PEI-PLGA-PEG-CAG/pZNF580 (91.99 ± 1.52%) groups was significantly higher than that of the positive control group Lip2000/pZNF580 (85.03 ± 2.21%). In addition, the results of the in vitro angiogenesis assay showed that the C-GQDs-PEI-PLGA-PEG-CAG/pZNF580 and N-GQDs-PEI-PLGA-PEG-CAG/pZNF580 groups had significantly higher angiogenesis-promoting ability than the positive control group, Lip2000/pZNF580.The present study provides a highly efficient and low-toxic method to promote endothelial cell migration in the field of regenerative medicine and a low-toxicity strategy to promote endothelial layer formation, which provides new possibilities for future vascular regeneration therapy.
Collapse
Affiliation(s)
- Xinghong Duo
- School of Chemistry and Chemical Engineering, Qinghai University for Nationalities, Xining, Qinghai, 810007, P. R. China.
- Key Laboratory of National Ethnic Affairs Commission of Resource Chemistry and Ecological Environment Protection on Qinghai-Tibet Plateau, Xining, Qinghai, 810007, P. R. China
| | - Qirong Xu
- School of Chemistry and Chemical Engineering, Qinghai University for Nationalities, Xining, Qinghai, 810007, P. R. China.
- Key Laboratory of National Ethnic Affairs Commission of Resource Chemistry and Ecological Environment Protection on Qinghai-Tibet Plateau, Xining, Qinghai, 810007, P. R. China
| | - Chen Li
- School of Chemistry and Chemical Engineering, Qinghai University for Nationalities, Xining, Qinghai, 810007, P. R. China.
- Key Laboratory of National Ethnic Affairs Commission of Resource Chemistry and Ecological Environment Protection on Qinghai-Tibet Plateau, Xining, Qinghai, 810007, P. R. China
| | - Xiangyan Meng
- Institute of Disaster and Emergency Medicine, Tianjin University, Tianjin, 300072, P. R. China
| | - Yakai Feng
- School of Chemical Engineering and Technology, Tianjin University, Tianjin, 300350, P. R. China
- Key Laboratory of Systems Bioengineering (Ministry of Education), TianjinUniversity, Tianjin, 300072, P. R. China
| |
Collapse
|
3
|
Salvati A. The biomolecular corona of nanomedicines: effects on nanomedicine outcomes and emerging opportunities. Curr Opin Biotechnol 2024; 87:103101. [PMID: 38461749 DOI: 10.1016/j.copbio.2024.103101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Revised: 12/05/2023] [Accepted: 02/14/2024] [Indexed: 03/12/2024]
Abstract
Upon administration, nanomedicines adsorb a corona of endogenous biomolecules on their surface, which can affect nanomedicine interactions with cells, targeting, and efficacy. While strategies to reduce protein binding are available, the high selectivity of the adsorbed corona is enabling novel applications, such as for biomarker discovery and rare protein identification. Additionally, the adsorbed molecules can promote interactions with specific cell receptors, thus conferring the nanomedicine new endogenous targeting capabilities. This has been reported for Onpattro, a lipid nanoparticle targeting the hepatocytes via apolipoproteins in its corona. Recently, selective organ-targeting (SORT) nanoparticles have been proposed, which exploit corona-mediated interactions to deliver nanoparticles outside the liver. Strategies for corona seeding and corona engineering are emerging to increase the selectivity of similar endogenous targeting mechanisms.
Collapse
Affiliation(s)
- Anna Salvati
- Department of Nanomedicine & Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, A. Deusinglaan 1, 9713AV Groningen, the Netherlands.
| |
Collapse
|
4
|
Li X, Zou J, He Z, Sun Y, Song X, He W. The interaction between particles and vascular endothelium in blood flow. Adv Drug Deliv Rev 2024; 207:115216. [PMID: 38387770 DOI: 10.1016/j.addr.2024.115216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Revised: 01/25/2024] [Accepted: 02/14/2024] [Indexed: 02/24/2024]
Abstract
Particle-based drug delivery systems have shown promising application potential to treat human diseases; however, an incomplete understanding of their interactions with vascular endothelium in blood flow prevents their inclusion into mainstream clinical applications. The flow performance of nano/micro-sized particles in the blood are disturbed by many external/internal factors, including blood constituents, particle properties, and endothelium bioactivities, affecting the fate of particles in vivo and therapeutic effects for diseases. This review highlights how the blood constituents, hemodynamic environment and particle properties influence the interactions and particle activities in vivo. Moreover, we briefly summarized the structure and functions of endothelium and simulated devices for studying particle performance under blood flow conditions. Finally, based on particle-endothelium interactions, we propose future opportunities for novel therapeutic strategies and provide solutions to challenges in particle delivery systems for accelerating their clinical translation. This review helps provoke an increasing in-depth understanding of particle-endothelium interactions and inspires more strategies that may benefit the development of particle medicine.
Collapse
Affiliation(s)
- Xiaotong Li
- School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, PR China
| | - Jiahui Zou
- School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, PR China
| | - Zhongshan He
- Department of Critical Care Medicine and Department of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610000, PR China
| | - Yanhua Sun
- Shandong Provincial Key Laboratory of Microparticles Drug Delivery Technology, Qilu Pharmaceutical Co., LtD., Jinan 250000, PR China
| | - Xiangrong Song
- Department of Critical Care Medicine and Department of Biotherapy, Frontiers Science Center for Disease-related Molecular Network, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610000, PR China.
| | - Wei He
- School of Pharmacy, China Pharmaceutical University, Nanjing 2111198, PR China.
| |
Collapse
|